July 17, 2008 08:00 ET

CDEX Announces First Sales and Deliveries of ID2 Meth Scanner™

CDEX Sells and Delivers ID2 Meth Scanners™ for Methamphetamine Detection to U.S. Clients in the Law Enforcement and Home Inspection Markets, and to U.S. and International Distributors

TUCSON, AZ--(Marketwire - July 17, 2008) - CDEX Inc. (OTCBB: CEXI) announces its first sales and deliveries of ID2 Meth Scanners™ for methamphetamine detection to U.S. clients in the Law Enforcement and Home Inspection Markets, and to U.S. and international distributors. The ID2 Meth Scanner™ is a hand-held, battery operated device that detects trace amounts of methamphetamine (low nanogram range) on virtually any surface while in the continuous scan mode. It employs the same CDEX patented Enhanced Photoemission Spectroscopy technology used in the ValiMed™ System, currently saving lives in hospitals today.

"We are excited about the commercialization of the ID2 Meth Scanner following two years of extensive R&D, beta testing and market research by the CDEX Team," said Steve Schmidt, VP and General Manager of CDEX's Security Division. The scourge of methamphetamine abuse is growing exponentially around the world. It is estimated that over 13 million are addicted to methamphetamine in the U.S. alone, raising significant concerns of officials in law enforcement, homeland security, school systems and the border patrol, as well as the unsuspecting consumers purchasing homes and used automobiles. "Residue from use or production of methamphetamine in homes, schools, automobiles, hotels and public buildings raises serious health risks for those exposed," Schmidt continued. "CDEX plans to build an extensive distribution network around the world, particularly in countries where meth abuse, manufacturing or distribution is at dangerous levels. This marks the first step in that process."

About CDEX Inc.

CDEX is a technology development company, currently manufacturing and globally distributing advanced chemical detection products, based on its patented Enhanced Photoemission Spectroscopy technology. With this technology, the company is providing unique solutions to the challenges of identifying substances in difficult to monitor environments. CDEX technology is being adapted to market needs for medication validation, hazardous chemicals detection, and brand protection through analysis of counterfeit substances. Currently, CDEX is organized to serve the two critical markets encompassing our existing product lines -- Medication Safety and Security. The Valimed™ System product line is providing life-saving validation of high-risk medications and return narcotics in healthcare facilities and pharmacies. The ID2 Meth Scanner™ product line is a revolutionary new tool in the global battle against the growing scourge of methamphetamine abuse and its toxic impact on the general public. Corporate headquarters and R&D facilities are located in Tucson, Arizona with an international office in Paris, France. For more information, visit and or contact Steve Schmidt, VP Corporate Communications, ( at (520) 745-5172 x212.

Any Non-Historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other similar words. These statements pose risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Contact Information

  • Contact:
    Steve Schmidt
    VP Corporate Communications
    Email Contact
    (520) 745-5172 x212